Enterovirus Vaccine
Anadis gets key regulatory approval received for enterovirus 71 vaccine program
Published in Vaccine Weekly, August 16th, 2006
The enterovirus 71 (EV-71 or hand, foot, & mouth disease in children) project is one of high commercial significance to Anadis, offering the potential to contribute significant revenue commencing during the 2006/07 financial year. The commencement of the EV-71 hyperimmunization program has occurred as a result of significant and successful interaction between Anadis, Ltd., Australian Quarantine Inspection & Service, and Australian Pesticides & Veterinary Medicines Association whereby both independent...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly
Source: Vaccine Weekly (2006-08-16)
More Articles from Vaccine Weekly
- Avian Influenza Vaccine
Reverse-genetics-produced H5N1 bird flu vaccine protects ferrets - Candidiasis Vaccine
Vaccines show promise against disseminated and mucosal candidiasis - Chickenpox Vaccine
Live varicella vaccine benefits HIV-infected children with depressed CD4+ T cell counts - Polio Vaccine
Inactivated poliovirus vaccine derived from Sabin strains has been developed - Polio Vaccine
Worldwide oral polio vaccine cessation strategy is presented - Adenovirus Pathogenesis
Adenovirus type 2 and type 5 E1A genes are expressed at different levels - More from this issue of Vaccine Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
